New pill aims to tame heart disease inflammation

NCT ID NCT06031844

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested an experimental daily pill called DFV890 in 24 adults with coronary heart disease and high levels of inflammation (measured by hsCRP). The goal was to see if the drug could safely lower certain inflammatory markers linked to heart risk. Participants took the pill or a placebo for 12 weeks, and researchers measured changes in blood markers like IL-6 and IL-18.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DFV890
What this could lead to: If successful, this could point toward a new daily pill to lower inflammation and potentially reduce heart disease risk.
What could go wrong: This is a small, early-phase study (24 people) testing only inflammatory markers, not heart attacks or survival. The drug may not work in larger trials or could have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CORONARY HEART DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

coronary artery disorder Coronary Disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CORONARY HEART DISEASE

Contacts and locations

Locations

Excel Medical Clinical Trials LLC

Boca Raton, Florida, 33434, United States
Monument Health Clinical Research

Rapid City, South Dakota, 57701, United States
Novartis Investigative Site

Montreal, Quebec, H1T 1C8, Canada
Triad Clinical Trials LLC

Greensboro, North Carolina, 27410, United States
UF Health Science Center

Jacksonville, Florida, 32209, United States
Universal Research Group LLC

Tacoma, Washington, 98405, United States
Valley Clinical Trials

Northridge, California, 91325, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.